Pharmacogenomic Effect/ADR for Cetuximab (DBSNPE000161)

DocumentationBrowse all
Identifier
DBSNPE000161
Drug
Cetuximab (DB00002)
Interacting Gene/Enzyme
Low affinity immunoglobulin gamma Fc region receptor III-A
Gene Name
FCGR3A
UniProt ID
P08637
Defining Change(s)
G > Trs396991
Allele Name
Not Available
Genotype(s)
(G;T) / (T;T)
Type(s)
Effect Directly Studied
Groups
Not Available
Description
Patients with this genotype have increased progression-free survival time when using cetuximab to treat colorectal cancer.
References
  1. Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ: FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol. 2007 Aug 20;25(24):3712-8. [Article]